TY - CHAP
T1 - Vaccine development for varicella-zoster virus
AU - Sadaoka, Tomohiko
AU - Mori, Yasuko
N1 - Publisher Copyright:
© 2018, Springer Nature Singapore Pte Ltd.
PY - 2018
Y1 - 2018
N2 - Varicella-zoster virus (VZV) is the first and only human herpesvirus for which a licensed live attenuated vaccine, vOka, has been developed. vOka has highly safe and effective profiles; however, worldwide herd immunity against VZV has not yet been established and it is far from eradication. Despite the successful reduction in the burden of VZV-related illness by the introduction of the vaccine, some concerns about vOka critically prevent worldwide acceptance and establishment of herd immunity, and difficulties in addressing these criticisms often relate to its ill-defined mechanism of attenuation. Advances in scientific technologies have been applied in the VZV research field and have contributed toward uncovering the mechanism of vOka attenuation as well as VZV biology at the molecular level. A subunit vaccine targeting single VZV glycoprotein, rationally designed based on the virological and immunological research, has great potential to improve the strategy for eradication of VZV infection in combination with vOka.
AB - Varicella-zoster virus (VZV) is the first and only human herpesvirus for which a licensed live attenuated vaccine, vOka, has been developed. vOka has highly safe and effective profiles; however, worldwide herd immunity against VZV has not yet been established and it is far from eradication. Despite the successful reduction in the burden of VZV-related illness by the introduction of the vaccine, some concerns about vOka critically prevent worldwide acceptance and establishment of herd immunity, and difficulties in addressing these criticisms often relate to its ill-defined mechanism of attenuation. Advances in scientific technologies have been applied in the VZV research field and have contributed toward uncovering the mechanism of vOka attenuation as well as VZV biology at the molecular level. A subunit vaccine targeting single VZV glycoprotein, rationally designed based on the virological and immunological research, has great potential to improve the strategy for eradication of VZV infection in combination with vOka.
UR - http://www.scopus.com/inward/record.url?scp=85048634931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048634931&partnerID=8YFLogxK
U2 - 10.1007/978-981-10-7230-7_7
DO - 10.1007/978-981-10-7230-7_7
M3 - Chapter
C2 - 29896666
AN - SCOPUS:85048634931
T3 - Advances in Experimental Medicine and Biology
SP - 123
EP - 142
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -
